Compare

Dotmatics vs Revvity Signals

Both are enterprise scientific informatics suites for pharma R&D; Dotmatics grew by acquiring products, Revvity Signals carries over PerkinElmer's Signals line.

Side by side

Dotmatics Revvity Signals
Vendor Dotmatics (Insight Partners) Revvity Signals Software
Pricing model Quote only Quote only
Free tier No No
Deployment Cloud, Self-hosted Cloud
Open source No No
Best for Pharma, biotech and chemical R&D organizations needing one connected platform across chemistry, biology and lab data. Pharmaceutical and biotech R&D teams needing an enterprise ELN connected to biology and chemistry data.
Pricing

Enterprise contracts configured per organization; no public pricing.

Pricing has not been verified yet — see the vendor's site.

Enterprise SaaS sold through direct sales, configured per customer; no public pricing.

Pricing has not been verified yet — see the vendor's site.

Features
  • Electronic lab notebook (ELN)
  • Laboratory information management (LIMS)
  • Chemical and sample registration
  • Scientific data analysis and visualization
  • Instrument and assay data integration
  • Cross-discipline (chemistry/biology) data connection
  • Enterprise deployment and configuration
  • Electronic lab notebook (Signals Notebook)
  • Biological and chemical data capture
  • Sample and inventory management
  • Cross-instrument data mining and visualization
  • In vitro/in vivo study data tools (VitroVivo)
  • Enterprise SaaS deployment
  • Pharma and biotech R&D focus

Verdict

Dotmatics and Revvity Signals compete for the same buyer: a pharma, biotech or chemical R&D organization that needs to connect ELN, LIMS, sample/chemical data and instrument data across many teams, not a single lab's notebook. Both are sold as configured enterprise contracts with no public pricing, and both trace their current form to consolidation — Dotmatics built its suite by acquiring and integrating several separate products, backed by Insight Partners, while Revvity Signals is the scientific-software division carried over from PerkinElmer's Signals line after PerkinElmer split into Revvity (life sciences/diagnostics) and an applied-instruments business in 2023. The practical difference between them comes down to which existing systems and instrument landscape each already integrates with in your organization, which is a question no comparison page can answer generically.

Choose Dotmatics if

  • Chemical registration and cross-discipline (chemistry-plus-biology) data connection is a core requirement, not an add-on.
  • You want both cloud and self-hosted deployment options.
  • Your organization already uses other tools from Dotmatics' acquired product lineup.

Choose Revvity Signals if

  • You are already a PerkinElmer or Revvity instrument customer and want continuity with the Signals product line you know.
  • In vitro/in vivo study data tools (Signals VitroVivo) matter to your specific research workflows.
  • A pure enterprise SaaS deployment fits your infrastructure needs better than a self-hosted option.

What they share

Both are targeted squarely at pharmaceutical and biotech R&D rather than a single academic lab, both bundle electronic lab notebooking with broader data capture and analysis rather than selling a notebook alone, and both expect an implementation project rather than a self-serve signup — this is not software you evaluate by starting a free trial. If your organization is smaller than either vendor's typical customer, a combined but lighter platform such as Labguru or Sapio Sciences may be a better-sized fit than either enterprise suite.

The honest caveat

Neither vendor publishes pricing, and both are sold through a direct-sales, configure-to-your-workflow process — meaning the real comparison only becomes clear after a demo and a proposal scoped to your instrument landscape, user count and compliance needs. Do not shortlist either based on feature lists alone; ask each vendor for reference customers in your specific R&D discipline (chemistry-heavy versus biology-heavy) and weigh implementation timeline as heavily as the feature comparison.

Last reviewed September 22, 2026

In the index now